
Last week, OpenAI launched AI tools for health care organizations, including ChatGPT for Healthcare, designed to improve care and streamline administrative tasks.

Brooke is an associate editor for The American Journal of Managed Care® (AJMC®). She joined AJMC in 2023, where she produces content covering multiple disease states.
She has a BA in journalism from Seton Hall University. You can connect with Brooke on LinkedIn.

Last week, OpenAI launched AI tools for health care organizations, including ChatGPT for Healthcare, designed to improve care and streamline administrative tasks.

Risk-based vaccination strategies and clinical pathway integration could improve coverage and strengthen future influenza preparedness, according to Marco del Riccio, MD.

Nursing home capacity has declined since the COVID-19 pandemic, causing greater strain on postacute care, especially in rural areas.

Although influenza vaccine uptake remains low, improving access, recommendations, and trust may help close coverage gaps.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

Multidisciplinary care helps manage cardiac risks in breast cancer, allowing patients to continue treatment safely, says Eric H. Yang, MD.

EHR penicillin allergy flags do not often match allergist assessments, highlighting the need for improved evaluation processes.

Flu vaccination in older adults may prevent hospitalizations and cardiovascular events, saving lives and reducing health care costs, according to Marco del Riccio, MD.

Smart pill bottles may boost adherence to oral breast cancer therapies through daily reminders and tracking, though cost and technology barriers remain, says Steven Manobianco, MD.

The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy.

Population demographics and prevention efforts are key drivers of influenza burden, according to Marco del Riccio, MD.

Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.

Amrita Basu, PhD, says AI can transform health care by streamlining data, enhancing decision-making, and unlocking insights to improve patient outcomes.

Eric H. Yang, MD, emphasizes the need for collaboration and interventions to protect patients’ hearts during breast cancer treatment.

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.

These pieces highlight several newly approved therapies that expanded treatment options across multiple disease states.

This year's most-watched video evaluated how President Donald Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

A recent review suggests women with ovarian or colorectal cancer face a higher risk of developing the other, highlighting the need for surveillance.

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Studies indicate that ultrasound-based AI models significantly outperform sonographers in diagnosing ovarian cancer.

This year's top inflammation article highlighted the first FDA-approved treatment for patients with bronchiectasis.

This year's top ovarian cancer article highlighted gaps in physician knowledge of genetic testing that may affect patient care.

Industry leaders discuss how policy, pricing, and innovation will shape the future of oncology care and patient access.

Top pieces from 2025 spanned outbreaks, an FDA drug approval, and the impact of NIH grant terminations.

The San Antonio Breast Cancer Symposium fosters collaboration among experts, enhancing research and treatment strategies for breast cancer's complex landscape.

Experts at SABCS highlighted the aggressive nature of breast cancer in young women, emphasizing tailored management and support strategies.

The FDA approved subcutaneous amivantamab with recombinant human hyaluronidase for EGFR-mutated NSCLC based on the phase 3 PALOMA-3 trial.

Marco del Riccio, MD, explains that the Flunomics report helped to identify gaps in US vaccine coverage and influenza surveillance during the 2024-2025 season.

Today, the FDA issued new guidance allowing de-identified real-world evidence in certain medical device applications, removing a barrier to using large data sources.

COVID-19 vaccination during pregnancy lowers hospitalization and preterm birth risks, providing key guidance for maternal care strategies.

Published: October 21st 2024 | Updated: October 24th 2024

Published: September 26th 2025 | Updated:

Published: June 11th 2024 | Updated:

Published: September 19th 2024 | Updated:

Published: November 13th 2023 | Updated:

Published: September 13th 2024 | Updated:

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
